NATALIE CHASTANT: Open Payments
NPI 1669702403 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,615 in 63 payments from 27 companies in 2025. Trend: 2023 $1,207 · 2024 $1,725 · 2025 $2,615
Food & beverage: $1,317Long term medical supply or device loan: $1,196Education: $101
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 15 | $1,285 |
| Janssen Biotech, Inc. | 6 | $303 |
| Stemline Therapeutics Inc. | 4 | $146 |
| Daiichi Sankyo Inc. | 4 | $127 |
| Lilly USA, LLC | 3 | $127 |
| GlaxoSmithKline, LLC. | 6 | $94 |
| Geron Corporation | 2 | $47 |
| Merck Sharp & Dohme LLC | 2 | $46 |
| PFIZER INC. | 2 | $46 |
| Gilead Sciences, Inc. | 2 | $39 |
Products named: KISQALI, RYBREVANT, ELZONRIS, Enhertu, Fabhalta, JEMPERLI, RYTELO, OJJAARA.
Industry payments across TX — which companies pay providers there.
